Paul Edwards Posted May 19, 2014 Share Posted May 19, 2014 Treating the prostate tumour is generally not considered an option if a patient has metastatic disease. Instead, patients are treated with systemic therapies, starting with androgen deprivation therapy. Recent data has suggested that removal of the primary tumour could enhance cancer control and survival in some patients but there is no evidence in the form of clinical trials to support this. Researchers at The University of Texas MD Anderson Cancer Centre have now begun a clinical trial to determine whether treating the primary tumour has any oncologic benefit in patients with metastatic prostate cancer. In the trial patients with metastatic prostate cancer receive systemic hormone treatment for 6 months and then are randomly assigned to continue hormone treatment only or continue hormone treatment and also undergo definitive treatment of the primary tumour. Dr Ana Aparicio, a one of the researchers in the trial said: “We think treating the primary tumour will help some people a lot, some people a little, and some people not at all. It is too early to recommend definitive intervention to the primary tumour as standard therapy in patients with metastatic prostate cancer outside a clinical trial.” More information about the trial is available at http://www2.mdanderson.org/depts/oncolog/articles/14/3-mar/3-14-3.html Link to comment Share on other sites More sharing options...
This topic is now archived and is closed to further replies.